Calebin A Cholesterol Management via Lipid Profile Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods are inadequate in effectively managing hypercholesterolemia by reducing LDL and increasing HDL cholesterol levels, and in preventing the progression of atherosclerosis and hypertriglyceridemia-induced conditions.
Innovation Solution
Administering therapeutically effective amounts of Calebin A orally to mammals to reduce circulating cholesterol levels, lower LDL and VLDL, and increase HDL, thereby aiding in the prevention and slowing of atherosclerosis and hypertriglyceridemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic methods are used to manage hypercholesterolemia, then treatment is provided, but they are inadequate in effectively reducing LDL and increasing HDL cholesterol levels
Solution Approach 1:
The patent changes the chemical parameter by introducing Calebin A, a specific compound with novel structural characteristics, to achieve superior cholesterol management effects compared to existing therapies. This parameter change in chemical composition directly addresses the inadequacy of current methods in effectively modifying lipid profiles.
Solution Approach 2:
The patent identifies and utilizes Calebin A, a naturally occurring compound found in Curcuma species, copying its beneficial hypolipidemic effects for therapeutic use. This approach leverages the natural compound's proven ability to reduce LDL and increase HDL, providing a more effective treatment than synthetic alternatives.
2Reliability
If current therapeutic methods are used, then treatment is provided, but they fail to prevent the progression of atherosclerosis and hypertriglyceridemia-induced conditions
Solution Approach 1:
The patent applies preliminary anti-action by using Calebin A to prevent the formation and progression of atherosclerotic plaques before they cause significant vascular damage. The compound intervenes early in the pathogenic process, inhibiting lipid deposition and vascular inflammation, thereby preventing atherosclerosis progression and protecting against hypertriglyceridemia-induced conditions.
Data Source
AI summary
Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.